Inflationary Pressures and Interest Rates: The FOMC minutes revealing the Fed's inflation stance are critical. For ALBT, a biotechnology company, higher interest rates could increase borrowing costs for R&D and expansion, potentially impacting its growth initiatives and overall valuation, especially given its current unprofitability.

Capital Availability and Risk Appetite: As a smaller, clinical-stage biotechnology company involved in diverse ventures (diagnostics, cellular therapy, AI), ALBT relies heavily on capital raises. Global market conditions, including investor risk appetite, can significantly affect its ability to secure funding through private placements or other means, impacting its operational runway and development timelines.

Technological Advancements and Competition in AI/Healthcare: The company's expansion into Agentic AI video platforms and its core biotechnology focus mean it is highly susceptible to rapid technological shifts and intense competition. Macro trends in AI innovation and healthcare breakthroughs directly influence its market positioning and potential for adoption of its products and services.